Patent intelligence · US
US 11291672
Betamethasone oral spray formulation and method of use to treat ataxia
Betamethasone oral spray formulation and method of use to treat ataxia
Patent details — US 11291672
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 5, 2022
- Expiration
- Mar 31, 2042
- Applicant
- GRACE THERAPEUTICS INC.
- Claims
- 25
- CPC classes
- A61K, A61K31/573, A61K47/02, A61K47/12
Quick answer
US 11291672 (Betamethasone oral spray formulation and method of use to treat ataxia) is held by GRACE THERAPEUTICS INC.. Status: granted. Granted Apr 5, 2022. Expires Mar 31, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GRACE THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/573, A61K47/02, A61K47/12, A61K47/26, A61K9/0053
More from GRACE THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12414943
Nimodipine parenteral administration
granted -
US 12049487
Universal chimeric antigen receptor T-cell preparation technique
granted -
US 11840575
Engineered immune cells targeting BCMA and their uses thereof
granted -
US 11484501
Mechanochemical activated dry amorphisation by milling equilibrium between ap mesoporous silica
granted -
US 11478424
Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica
granted -
US 11478420
Vaginal probiotic products and related processes
granted -
US 11052029
Cation compatible metal oxides and oral care compositions containing the metal oxides
granted
Frequently asked questions
What is US patent 11291672?
US 11291672 (Betamethasone oral spray formulation and method of use to treat ataxia) is held by GRACE THERAPEUTICS INC.. Status: granted. Granted Apr 5, 2022. Expires Mar 31, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11291672?
GRACE THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 11291672 expire?
Our index shows an expiration date of Mar 31, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.